![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF736 |
Gene summary for ZNF736 |
![]() |
Gene information | Species | Human | Gene symbol | ZNF736 | Gene ID | 728927 |
Gene name | zinc finger protein 736 | |
Gene Alias | ZNF736 | |
Cytomap | 7q11.21 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | B4DX44 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
728927 | ZNF736 | HCC1_Meng | Human | Liver | HCC | 2.28e-08 | 9.97e-03 | 0.0246 |
728927 | ZNF736 | HCC1 | Human | Liver | HCC | 3.29e-04 | 1.57e+00 | 0.5336 |
728927 | ZNF736 | S014 | Human | Liver | HCC | 3.44e-06 | 2.35e-01 | 0.2254 |
728927 | ZNF736 | S015 | Human | Liver | HCC | 2.99e-06 | 2.76e-01 | 0.2375 |
728927 | ZNF736 | S016 | Human | Liver | HCC | 3.44e-06 | 2.33e-01 | 0.2243 |
728927 | ZNF736 | S027 | Human | Liver | HCC | 2.94e-02 | 2.91e-01 | 0.2446 |
728927 | ZNF736 | S028 | Human | Liver | HCC | 7.14e-17 | 5.31e-01 | 0.2503 |
728927 | ZNF736 | S029 | Human | Liver | HCC | 9.18e-10 | 3.79e-01 | 0.2581 |
728927 | ZNF736 | PTC04 | Human | Thyroid | PTC | 9.61e-05 | 1.18e-01 | 0.1927 |
728927 | ZNF736 | PTC05 | Human | Thyroid | PTC | 4.48e-08 | 2.57e-01 | 0.2065 |
728927 | ZNF736 | PTC06 | Human | Thyroid | PTC | 1.24e-13 | 2.91e-01 | 0.2057 |
728927 | ZNF736 | PTC07 | Human | Thyroid | PTC | 1.25e-05 | 1.07e-01 | 0.2044 |
728927 | ZNF736 | ATC11 | Human | Thyroid | ATC | 3.84e-06 | 4.39e-01 | 0.3386 |
728927 | ZNF736 | ATC13 | Human | Thyroid | ATC | 7.25e-48 | 7.87e-01 | 0.34 |
728927 | ZNF736 | ATC3 | Human | Thyroid | ATC | 1.76e-09 | 4.85e-01 | 0.338 |
728927 | ZNF736 | ATC5 | Human | Thyroid | ATC | 1.24e-44 | 8.53e-01 | 0.34 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF736 | SNV | Missense_Mutation | c.1171N>G | p.His391Asp | p.H391D | B4DX44 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
ZNF736 | SNV | Missense_Mutation | c.200G>A | p.Arg67Lys | p.R67K | B4DX44 | protein_coding | deleterious(0.05) | benign(0) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | |
ZNF736 | insertion | Nonsense_Mutation | novel | c.742_743insCTTTGGTAGTCTTTCTTT | p.Lys248delinsThrLeuValValPheLeuTer | p.K248delinsTLVVFL* | B4DX44 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
ZNF736 | SNV | Missense_Mutation | novel | c.342G>T | p.Lys114Asn | p.K114N | B4DX44 | protein_coding | deleterious(0.04) | benign(0.001) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZNF736 | SNV | Missense_Mutation | novel | c.484N>A | p.Glu162Lys | p.E162K | B4DX44 | protein_coding | tolerated(0.34) | benign(0.003) | TCGA-C5-A8XK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
ZNF736 | SNV | Missense_Mutation | c.880T>G | p.Tyr294Asp | p.Y294D | B4DX44 | protein_coding | deleterious(0) | possibly_damaging(0.602) | TCGA-AA-3530-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ZNF736 | SNV | Missense_Mutation | novel | c.1220N>A | p.Ser407Asn | p.S407N | B4DX44 | protein_coding | tolerated(1) | benign(0.012) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
ZNF736 | SNV | Missense_Mutation | c.14N>A | p.Thr5Lys | p.T5K | B4DX44 | protein_coding | deleterious(0.01) | probably_damaging(0.937) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZNF736 | SNV | Missense_Mutation | novel | c.873C>G | p.Asn291Lys | p.N291K | B4DX44 | protein_coding | deleterious(0) | benign(0.067) | TCGA-AY-4070-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5-fu | PD |
ZNF736 | SNV | Missense_Mutation | novel | c.579A>C | p.Lys193Asn | p.K193N | B4DX44 | protein_coding | tolerated(0.1) | benign(0.023) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |